Joe Odell Lost a $20M Home Infusion Pharmacy When One Drug's Reimbursement Cut 90%

The Setup Joe Odell grew up blue-collar in Reading, California, served enlisted in the military from 2005 to 2013, and worked his way through Bay Area tech BD roles to a Haas MBA in 2020. He met Jess Patterson, a CFO-background operator, at Berkeley. They launched a traditional search fund in March 2021, raising $800K from 24 investors. Odell brought sales and go-to-market; Patterson brought finance, ops, and HR. The partnership thesis was complementary skills for a complex operating business. The Deal In December 2021 they closed on Pharmacy Specialists, a home infusion compounding pharmacy operating clean rooms in Dallas and Houston. The business converted powder medications (antibiotics, IVIG, cardiology drugs) to injectable liquid and shipped to homebound patients, mostly via FedEx. - Revenue: $20M (up from $15M prior year) - EBITDA: $4M+ at 20% margins - Purchase price: ~$26M, 6.5x EBITDA - Capital stack: $12M traditional debt (3x), $4M seller note (1x), 2x equity - Seller retained under 10% and stayed on as advisor - Headcount: ~100 Thesis: aging-population tailwinds on life-sustaining prescriptions, low churn, 20% margins supporting aggressive leverage, and multiple expansion arbitrage if EBITDA reached $5-7M. First 100 Days The cash crunch hit immediately. Working capital at close was under $2M. January recertifications reset 400+ patients' prior authorizations at once, stalling a month of cash collections. Then four compounding problems surfaced: - A sales rep representing 20% of revenue left around close (not disclosed in diligence) - Patient census between Dallas and Houston was duplicated, inflating the growth trajectory - Daptomycin reimbursement shifted to an unprofitable coding structure - Payables were running on immediate terms Odell and Patterson split roles. She managed cash preservation and stretched vendors to net-30. He rebuilt process maps, fixed reimbursement coding, deduplicated census, and personally drove deliveries across Arkansas, Louisiana, East Texas, and Oklahoma during ice storms when FedEx couldn't. Operating Moves By summer 2022 the business had stabilized. Q4 2022 ran at $1M EBITDA per month and the year closed over $20M in revenue. The operating plan worked. What it couldn't fix was the input side. In early 2024 the manufacturer of the core cardiology drug cut average wholesale price by 90%. That one line carried roughly a third of revenue but half of EBITDA. Same patients, same trucks, same clean rooms, half the gross profit gone overnight. EBITDA dropped from $4M to about $1M. Debt service was $200K per month. They ran on fumes for 18 months with two rounds of layoffs, from 100 employees to about 20. In September 2024 Odell chose to shut down rather than take a rescue capital injection he couldn't promise to protect. Operating Lessons - Underwrite supplier concentration the way you underwrite customer concentration. One drug, one manufacturer, one AWP decision ended the business. - In reimbursement-driven healthcare, gross margin is not yours to control. Model the downside where a payor or manufacturer moves price against you. - Cash at close is a variable, not a given. Sub-$2M working capital on a $20M healthcare...